Nicola Lucio Liberato

Summary

Affiliation: Ospedale Civile
Country: Italy

Publications

  1. ncbi request reprint Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer
    Nicola Lucio Liberato
    Azienda Ospedaliera della Provincia di Pavia, Divisione di Medicina Interna, Ospedale Civile, Casorate Primo, Pavia, Italy
    J Clin Oncol 25:625-33. 2007
  2. doi request reprint Adding docetaxel to cisplatin and fluorouracil in patients with unresectable head and neck cancer: a cost-utility analysis
    N L Liberato
    Department of Internal Medicine, Azienda Ospedaliera della Provincia di Pavia, Casorate Primo, Italy
    Ann Oncol 23:1825-32. 2012
  3. ncbi request reprint Clinical and economic issues in the treatment of advanced breast cancer with bisphosphonates
    Nicola Lucio Liberato
    Division of Internal Medicine, Civil Hospital, Voghera, Italy
    Drugs Aging 20:631-42. 2003

Detail Information

Publications3

  1. ncbi request reprint Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer
    Nicola Lucio Liberato
    Azienda Ospedaliera della Provincia di Pavia, Divisione di Medicina Interna, Ospedale Civile, Casorate Primo, Pavia, Italy
    J Clin Oncol 25:625-33. 2007
    ..To evaluate the cost-effectiveness of 12-month adjuvant trastuzumab therapy in women with high-risk human epidermal growth factor receptor 2 (HER2) -positive early breast cancer...
  2. doi request reprint Adding docetaxel to cisplatin and fluorouracil in patients with unresectable head and neck cancer: a cost-utility analysis
    N L Liberato
    Department of Internal Medicine, Azienda Ospedaliera della Provincia di Pavia, Casorate Primo, Italy
    Ann Oncol 23:1825-32. 2012
    ..The aim of the study was to analyze the cost-utility of TPF in patients with unresectable disease...
  3. ncbi request reprint Clinical and economic issues in the treatment of advanced breast cancer with bisphosphonates
    Nicola Lucio Liberato
    Division of Internal Medicine, Civil Hospital, Voghera, Italy
    Drugs Aging 20:631-42. 2003
    ..Probably, country- and drug-specific policies might increase the efficiency of this treatment. Further outcomes research is required to assess these agents more fully...